Articles tagged with Sepsis
Mayo Clinic researchers propose a new understanding of how sepsis arises, suggesting that normal body substances may cause some cases of the deadly condition. They identify a critical receptor that triggers the sepsis cycle, which could lead to new treatments.
A large study found that statin use was associated with a 19% reduced risk of sepsis in patients with cardiovascular disease. The study analyzed data from over 69,000 people and suggested that statins may be used to prevent sepsis in this population.
A study reveals that angiopoietin-2 (Ang-2) plays a pivotal role in acute respiratory distress syndrome (ARDS), a condition affecting 40% of patients with sepsis. Elevated Ang-2 levels can cause leakiness in lung blood vessels, impairing lung function and leading to trouble breathing.
A study found that 72% of children with meningococcal disease exhibited early symptoms of infection, such as leg pain and abnormal skin color, which developed on average 8 hours before the classic symptoms appeared. This discovery could lead to faster diagnosis and improved treatment outcomes.
ELBW preterm infants who develop infections are at risk of adverse neurodevelopmental outcomes, including cerebral palsy, low Bayley Scales scores, and vision impairment. Infections during the neonatal period also lead to impaired head growth, a known predictor of poor neurodevelopmental outcome.
Research found that neonatal infections in low-birth-weight infants are associated with impaired neurodevelopmental outcomes, including cerebral palsy, vision impairment, and cognitive delays. Infected infants also had impaired head growth, a predictor of poor neurodevelopmental outcome.
In a breakthrough discovery, Stanford researchers have found that mast cells can provide protection from sepsis by destroying a molecule that contributes to the pathology and death associated with this bacterial infection. The study reveals a new role for mast cells in limiting damage caused by endothelin-1.
A study published in Critical Care found that severe sepsis affects around 5% of cancer patients hospitalized in the US, resulting in a mortality rate nearly five times higher than non-cancer patients. Early antibiotic treatment could significantly improve cancer survival rates.
A recent study by Cincinnati Children's Hospital Medical Center suggests that human milk can significantly reduce the risk of severe infections in extremely low birth weight infants. The research analyzed data from 1270 infants and found that those who received human milk had a lower incidence of sepsis compared to those who did not.
A study by Johns Hopkins Medicine found that postoperative sepsis is the most common treatment-related injury in hospitals, associated with significant increases in length of stay, charges, and mortality. The unintended re-opening of surgically closed wounds was also a major concern, linked to increased hospital stays and costs.
A recent study found that a sepsis drug, DAA, can significantly reduce hospital care and mortality rates among older patients. The study, which followed 386 patients over two years, showed that the drug improved survival rates and reduced the need for intensive care.
Early-onset group B streptococcal (EOGBS) infection affects one in 1000 newborns, but diagnostic tests often yield false-negative results. A new study suggests that active surveillance and alternative diagnostic methods could improve accurate diagnosis and prevention of this potentially deadly disease.
TSRI scientists have identified rare genetic mutations in the TLR4 gene that increase susceptibility to meningococcal sepsis, a devastating disease with a 12% case fatality rate. The study suggests that individuals with these mutations may be protected from severe sepsis through prophylactic treatment.
A recent study by Emory University and CDC found a significant increase in sepsis cases and deaths in the US over a 22-year period. The study suggests that factors such as antibiotic resistance, invasive procedures, and improvements in care among immunocompromised individuals are contributing to this trend.
Two new studies highlight the severity of sepsis in young US children, with infants and low-birth-weight babies at highest risk. In contrast, imported malaria cases in European countries pose a growing health threat, while disruptions to ICU patients' sleep patterns remain poorly understood.
Researchers found a 6.9% annual increase in complex severe sepsis cases and a slight increase in ICU admissions. Despite this, sepsis-related mortality decreased by approximately 4% over the seven-year period.
Researchers found that anti-inflammatory agents are more effective in patients at higher risk of death from sepsis. Spiral computed tomography (CT) scans can help identify up to four times more lung cancers than chest x-rays, with 70% of tumors still in Stage 1.
A recent study found a significant change in the types of bacteria involved in early-onset sepsis in low-birth-weight infants, with an increase in E. coli cases and antibiotic-resistant strains. The shift raises concerns about the impact of increasing antibiotic use during labor on these vulnerable infants.
A new study by Emory University and CDC reveals a surge in sepsis cases across the US, with significant increases in hospitalizations among specific demographics. The incidence of sepsis rose in both children and adults over a 20-year period, with gram-positive infections becoming more prevalent.
Scientists propose sCD14 as a protective mechanism against LPS-mediated inflammation. Studies show that increasing sCD14 levels can neutralize LPS and reduce inflammatory cytokine secretion. The protein's role in sepsis treatment is still uncertain, but its discovery offers new hope for managing systemic effects of bacterial infections.
Researchers at the University of Michigan have found that blocking C5a, a protein that normally activates the immune system, provides significant protection against sepsis in animal studies. In sepsis-induced rats, blocking C5a resulted in more than half surviving compared to just 5% in a control group.